Right to participate in the general meeting
Shareholders who wish to participate at the annual general meeting shall:

• on Wednesday 7 May 2025 (the record date), be registered in the share register kept by Euroclear Sweden AB in their own names (not nominee-registered shares), and
• notify the Company of his or her intention to attend the general meeting so that the notification is received by the Company no later than Friday 9 May 2025. Notification shall be made via e-mail to alexander.hase@lindahl.se or by post to the address Advokatfirman Lindahl KB, att. Alexander Hase, Box 1203, 751 42 Uppsala. Upon notification, the shareholder's name, social security number or organization number (or equivalent) and preferably address, telephone number, shareholding, details on advisors (maximum two), and, where applicable, details of deputies or proxies.

Nominee-registered shares
Shareholders who have nominee-registered shares shall, in order to exercise their voting rights and participate in the meeting, register for the meeting, and temporarily register the shares in their own names with Euroclear Sweden (so-called voting rights registration), so that the person concerned is included in the share register kept by Euroclear Sweden as of the record date, i.e. Wednesday 7 May 2025. This means that shareholders need to notify the concerned trustee of their wish in this regard well in advance of this date. Voting rights registration requested by shareholders in such a time that the registration has been made by the relevant trustee no later than Friday 9 May 2025 will be taken into in the share register.

Proxy
Shareholders who intend to attend by proxy shall issue a dated power of attorney. If the power of attorney is issued by a legal entity, a copy of the registration certificate or equivalent for the legal entity needs to be attached. The power of attorney may be valid for a maximum of five years from issuance. The power of attorney in original (together with any authorization documents, such as registration certificate) should be sent well in advance of the meeting to the Company at the above address. A blank proxy form is available on the Company's website, www.prostatypegenomics.com.

Number of shares and votes
At the time of issuing this notice, there are a total of 6,835,213 shares and votes in the Company.

Proposed agenda

1. Opening of the general meeting and election of the chairperson of the general meeting
2. Preparation and approval of the voting list
3. Election of one or two persons to verify the minutes
4. Determination as to whether the meeting has been duly convened
5. Approval of the agenda
6. Presentation of the annual report and the auditor's report
7. Resolutions on:
   1. the adoption of the income statement and the balance sheet
   2. allocation of the Company's result according to the adopted balance sheet, and
   3. discharge from liability for each of the members of the board of directors and the CEO
8. Determination of the number of board members and board deputies
9. Determination of remuneration to the board of directors and the auditor
10. Election of members of the board of directors, chairman of the board of directors and any board deputies
11. Election of auditor/auditing company
12. Resolution on the nomination committee for the next annual general meeting
13. Resolution on a) approval of the board’s proposal for a resolution to amend the articles of association and b) the subsequent approval by the general meeting of the board’s resolution on 15 April 2025 regarding new issue of units with preferential rights for existing shareholders
14. Resolution on authorization regarding so-called over-allotment
15. Resolution on authorization regarding issue to guarantors
16. Resolution on introducing incentive program 2025/2029
17. Resolution on general authorization to issue shares
18. Closing of the general meeting

Proposals to resolutions
Item 1 – Election of chairman of the general meeting
The nomination committee proposes that Mattias Prage, lawyer at Advokatfirman Lindahl, is elected as chairperson of the general meeting.

Item 7b) – Allocation of the Company’s result according to the adopted balance sheet
The board proposes that no dividend be paid for the financial year 2024 and that the Company's results be balanced carried forward.

Item 8 – Determination of the number of board members and board deputies
The nomination committee proposes that the annual general meeting resolve that the board shall consist of five (5) board members, without deputy directors.

Item 9 – Determination of remuneration to the board of directors and the auditor
The nomination committee proposes that the annual general meeting resolves that a board fee of SEK 160,000 shall be paid to the chairperson and SEK 80,000 to each other member of the board, unless the member in question is prevented from receiving such a fee due to current guidelines of the member's employer. The remuneration is unchanged compared to the last annual general meeting.

The nomination committee proposes that compensation to the auditor shall be paid as per approved invoice.

Item 10 - Election of members of the board of directors, chairman of the board of directors and any board deputies
The nomination committee proposes re-election of Anders Lundberg, Michael Häggman, Mattias Prage, Håkan Englund and Jörgen Dahlström as ordinary members for the time until the next annual general meeting. Johan Waldhe has declared that he is not available for re-election due to other commitments. Anders Lundberg is proposed for re-election as chairperson of the board.

Item 11 – Election of auditor/auditing company
The nomination committee proposes re-election of the registered auditing company Grant Thornton Sweden AB, with Joakim Söderin as chief auditor, for the time until the next annual general meeting.

Item 12 – Proposal for principles for the compensation and work of the nomination committee for the annual general meeting 2026
The nomination committee proposes that the annual general meeting resolves to establish a nomination committee for the annual general meeting 2026 according to the following principles.

The meeting instructs the chairperson of the board to contact the three largest shareholders in terms of votes according to Euroclear's latest printout of the share register, who each appoint a member of the nomination committee. If one of the three largest shareholders does not wish to appoint a member of the nomination committee or does not respond to the request, the fourth largest shareholder shall be asked and so on until the nomination committee consists of three members. The members of the nomination committee shall be published on the company's website no later than six months before the next annual general meeting.
The mandate period for the appointed nomination committee shall run until a new election committee is appointed according to the mandate from the next annual general meeting.

The nomination committee appoints a chairperson within the group. The chairperson of the board or another board member shall not be chairperson of the nomination committee.

If a member leaves the nomination committee before its work is completed and if the nomination committee considers that there is a need to replace this member, the nomination committee shall appoint a new member according to the principles above, however based on the ownership conditions then in force. Changes in the composition of the election committee shall be made public.

No remuneration shall be paid to the members for their work in the election committee.

The nomination committee shall submit proposals for resolutions on the following issues for the annual general meeting 2026.

1. Election of chairperson at the meeting.
2. Determination of the number of board members.
3. Determination of remuneration and other compensation to the board of directors and its committees, with division between the chairperson and other members.
4. Determination of remuneration to auditors.
5. Election of board members and board chairperson.
6. Election of auditors.
7. Proposal for principles for the nomination committee's composition and work ahead of the annual general meeting 2027.

Item 13 – Resolution on a) approval of the board’s proposal for a resolution to amend the articles of association and b) the subsequent approval by the general meeting of the board’s resolution on 15 April 2025 regarding new issue of units with preferential rights for existing shareholders
a) Board’s proposal for a resolution to amend the articles of association
In order to enable the new issue according to item b) below, the board proposes that the general meeting resolve that the limits in the articles of association for share capital and number of shares are changed as follows.

The limits in the articles of association for share capital are changed from the current minimum of SEK 500,000 and maximum of SEK 2,000,000 to a minimum of 2,500,000 and a maximum of 10,000,000. The limits for shares are changed from the current minimum of 5,000,000 and maximum of 20,000,000 to a minimum of 25,000,000 and a maximum of 100,000,000. § 4 and § 5 in the articles of association will therefore read as follows:

Ҥ 4 Share capital
The share capital shall be not less than SEK 2,500,000 and not more than SEK 10,000,000.

§ 5 Number of shares
The number of shares shall be not less than 25,000,000 and not more than 100,000,000.”

a) Subsequent approval by the general meeting of the of the board’s resolution on 15 April 2025 regarding new issue of units with preferential rights for existing shareholders
On 15 April 2025, the board of directors of the Company resolved, subject to the subsequent approval by the general meeting, to increase the Company's share capital by a maximum of SEK 4,784,649.10 (of which a maximum of SEK 2,734,085.20 is attributable to an increase due to the issue of shares and a maximum of SEK 2,050,563.90 is attributable to an increase due to the issue of warrants) by issuing a maximum of 6,835,213 so-called units with preferential rights for existing shareholders in accordance with the following terms and conditions.

1. Each unit consists of four (4) shares and three (3) warrants of series TO 5. This means that a maximum of 27,340,852 new shares and a maximum of 20,505,639 new warrants can be issued.
2. The right to subscribe for units with preferential rights shall be granted to those who are registered as shareholders in the Company on the record date of the rights issue, whereby each such shareholder shall be entitled to one (1) unit right for each existing share. One (1) unit right entitles the holder to subscribe for one (1) unit.
3. In the event that not all units are subscribed for with unit rights, the board of directors shall, within the limit of the maximum amount of the rights issue, resolve on the allocation of units not subscribed for with preferential rights. Such allocation shall primarily be made to subscribers who have subscribed for units with unit rights, regardless of whether the subscriber was a shareholder on the record date for the rights issue or not, and, in the event of oversubscription, pro rata in relation to the number of units subscribed for with unit rights. Secondly, allocation shall be made to those who have subscribed for units without unit rights and, in the event of oversubscription, pro rata in relation to the number of units subscribed for in the application and, to the extent that allocation cannot be made pro rata, by drawing lots. Thirdly, allocation shall be made to the guarantors in accordance with the terms of issued guarantee commitments.
4. The record date for participation in the rights issue shall be 19 May 2025.
5. Subscription of units with preferential rights shall be made in cash or set-off during the period from 21 May 2025 to 4 June 2025. The board of directors shall have the right to extend the subscription and payment period.
6. Subscription of units without preferential rights shall be made by subscription on a subscription list during the same time as stated in the previous point, i.e. during the period from 21 May 2025 to 4 June 2025. Payment shall be made in cash or set-off no later than three (3) banking days after the notification of allotment has been sent. The board of directors shall have the right to extend the subscription and payment period.
7. Each unit is issued at a price of SEK 4 per unit, which corresponds to a subscription price of SEK 1 per share. The warrants are issued free of charge.
8. Each warrant of series TO 5 shall entitle the holder to subscribe for one (1) new share in the Company at a subscription price corresponding to 70 percent of the 20-day volume-weighted average price prior to the second day before the exercise period, however, not less than the shares quota value (SEK 0.10) and not more than SEK 1.50. If the subscription price exceeds the quota value of the shares, the excess amount shall be added to the unrestricted share premium reserve. Subscription of shares by virtue of warrants of series TO 5 shall be made in accordance with the terms and conditions for the warrants during the period 3 September 2025 to 17 September 2025. The warrants shall otherwise be subject to the terms and conditions set out in separate appendix.
9. The right issue resolution requires amendment to the articles of association.
10. The new shares carry the right to dividends from the first time on the record date for dividends that occurs immediately after the rights issue has been registered with the Swedish Companies Registration Office and the shares have been entered in the share register kept by Euroclear Sweden AB. Shares issued as a result of new subscriptions based on warrants carry the right to dividends for the first time on the record date for dividends that occurs immediately after the new subscription has been registered with the Swedish Companies Registration Office and the shares have been entered in the share register kept by Euroclear Sweden AB.
11. The CEO, or the person appointed by the board of directors, shall be entitled to make such minor adjustments as may be required in connection with the execution of the resolution and in connection with the registration of the resolution with the Swedish Companies Registration Office and Euroclear Sweden AB.

Item 14 – Resolution on authorization regarding so-called over-allotment
The board of directors proposes that the general meeting authorizes the board of directors to, on one or more occasions during the period until 30 July 2025, resolve on the issue of shares and/or warrants (units) through so-called over-allotment, which may be used in the event of oversubscription in the preferential rights issue according to item 13. A rights issue resolved upon by support of this authorization may increase the Company’s share capital by not more than SEK 717,697.40 (of which not more than SEK 410,112.80 is attributable to an increase due to the issue of shares and not more than 307,584.60 is attributable to an increase due to the issue of warrants) through an issue of not more than 1,025,282 units, which corresponds to approximately 15 percent of the total amount of units which can be issued in the preferential rights issue.

A rights issue in accordance with this authorization shall be made on terms corresponding to the terms of the preferential rights issue according to item 13. Such an issue will be made with deviation from the shareholders' preferential rights and with the condition that payment may be made by set-off. The reason for the deviation in such a case is to meet the interest in participating in the rights issue and thereby further strengthen the Company's financial position. The persons/entities entitled to subscribe in an issue decided on the basis of this authorization shall be those who have applied for subscription in the rights issue, but who have not received full allotment in accordance with their subscription.

The CEO, or whoever the board of directors appoints, shall have the right to make the minor adjustments that may be required in connection with registration of the resolution with the Swedish Companies Registration Office and Euroclear Sweden AB.

Item 15 – Resolution on authorization regarding issue to guarantors
The board of directors proposes that the general meeting, in connection with the general meeting's approval of the board of directors' resolution on the preferential rights issue according to item 13, authorizes the board of directors to, on one or more occasions during the time leading up to the next annual general meeting, resolve to increase the Company's share capital within the limits of the articles of association by issuing shares and/or warrants (units). The authorization may only be used to issue units to those who acted as guarantors in the preferential rights issue according to item 13. If the board of directors utilizes the authorization, it may therefore be done with a deviation from the shareholders' pre-emptive right and with the condition that payment may be made by set-off. The reason for the deviation in such a case is for the Company to be able to fulfill contractual obligations towards the guarantors in the preferential rights issue.

The CEO, or whoever the board of directors appoints, shall have the right to make the minor adjustments that may be required in connection with registration of the resolution with the Swedish Companies Registration Office and Euroclear Sweden AB.

Item 16 – Resolution on introducing incentive program 2025/2029
The board of directors of the Company proposes that the general meeting resolves (A) on the implementation of an employee stock option program (the "Program 2025/2029" or the "Program") intended for employees and key persons in the Company or the Company's group, (B) on a directed issue of warrants to the Company to ensure the Company's delivery of shares under the Program and to cover any cash flow effects due to social costs in connection with the Program and (C) on approval of transfer of warrants or shares in the Company to participants in the Program. Resolutions under items A, B and C above shall be made as one resolution and are thus conditional upon each other.

The Board considers it important and in the interest of all shareholders that the Group's employees and key persons, who are considered important for the Company's further development, have a long-term interest in a good value development of the Company's share. A personal long-term ownership commitment can be expected to contribute to an increased interest in the Company's operations and earnings development, as well as increase the participants' motivation and affinity with the Company and its shareholders. The Board also makes the assessment that the Program creates conditions to limit future salary costs, as the Program partly becomes part of the participants' total remuneration package and fully or partly replaces bonus programs.
The maximum dilution effect of the Program is estimated to amount to approximately ten (10) percent, provided that all options granted under the Program are exercised in full. The calculation shall be made in relation to the number of registered outstanding shares in the Company as of 30 September 2025. Note that the number of options and underlying warrants is limited to such maximum dilution as set out below. For the relation to previous incentive programs in the Company, see below.
This proposal has been prepared by the Board in consultation with external advisors.

A. Program 2025/2029
The Board of Directors proposes that the General Meeting resolves on the introduction of Program 2025/2029 on the following main conditions:

1. The program shall include not more than 5,000,000 employee stock options.
2. The stock options shall be granted free of charge to participants in the program.
3. The 2025/2029 Program shall cover employees and other key persons of the Company or the Group. Members of the Board of Directors do not participate in the Program. Employee stock options shall be offered and allocated to employees and other key persons in the Company or the group based on the participants' competence, merits, performance , importance to the Company and the participant's individual fixed remuneration. The options may also be granted to employees and key persons employed in the United States.

The offer of employee stock options shall be decided by the Board of Directors of the Company. Allocation may be made with a maximum of ten (10) percent of the Company's registered number of shares as of 30 of September 2025. The total number of employee stock options that may be offered to a participant shall be no more than fifty (50) percent of the allocable employee stock options.

1. Allocation of stock options is decided no later than 31st of October 2025. However, allocation may take place earlier or later following a specific decision by the Board of Directors.
2. Granted stock options vest over a period of three (3) years, with 1/3 vesting on each anniversary of the grant date. However, if the Board deems it appropriate for commercial reasons and/or to maintain the incentive function of the program, the Board may decide to deviate from this for one or more participants.
3. Vesting assumes that the participant is still employed by or has an assignment for the Company or a group company at any time when vesting takes place. If the participant ceases to be employed by or have an assignment for the Company or its group companies, further vesting shall not take place. However, the participant is entitled to retain and subsequently exercise already vested employee stock options even after the termination of the employment or assignment, unless the employment or assignment in the Company is terminated by notice or dismissal (or equivalent grounds for termination of an assignment agreement) due to the participant's failure to fulfill his/her obligations under the employment agreement, the agreement or law and regulation, in which case the Company's obligation to deliver shares, and the participant's possibility to exercise employee stock options to obtain shares, lapses in its entirety. However, if the Board of Directors deems it appropriate in an individual case, it may decide to derogate from this paragraph.
4. Participants may exercise granted and vested stock options during the period from 1st of November 2028 up to and including 1st of May 2029 (the "Exercise Period").
5. The stock options may be exercised to subscribe for shares in the Company, in accordance with the terms of the stock options, whereby certain strategic and operational targets may be set. Any targets will be set in advance by the Board of Directors or the CEO. The objectives should be objectively designed and related to the business. Examples of targets include sales and profit targets, development targets and share price.
6. Each employee stock option shall entitle the participant to acquire one (1) new share in the Company during the Exercise Period (after any target fulfillment in accordance with item 8 above), at an exercise price corresponding to 125 percent of the volume-weighted average price of the Company's share on Nasdaq First North Stockholm during a period of ten (10) trading days prior to the general meeting on 15 May 2025.
7. The right to participate in the Program is conditional upon the participant entering into an option agreement with the Company in the format specified by the Company. US citizens participating in the Program may be subject to special conditions. The board has the right to condition the exercise through conditions related to the business, such as operational objectives.
8. Issued employee stock options are not securities and may not be transferred, pledged or otherwise disposed of by the holder.
9. If, during the term of the employee stock options, the general meeting (or the board of directors by virtue of an authorization) should decide on a change in the number of shares in the Company (e.g. a reverse share split or a new issue of securities), the board of directors shall review the terms and conditions of the employee stock options and - if deemed appropriate and expedient in order to maintain the incentive function of the options - make changes to the terms and conditions (which may not, however, be to the disadvantage of the participant). The Board also has the corresponding possibility to review and amend the terms of the stock options if it is otherwise deemed appropriate and useful to maintain the incentive function of the options.
10. The Board of Directors shall be responsible for the design and management of the Stock Option Program 2025/2029 within the framework of the main terms and guidelines set out above. The Board of Directors is entitled, through the agreement with each participant, depending on, inter alia, residence, to make reasonable changes and adjustments to the terms and conditions of the employee stock options that are deemed appropriate or expedient, for example depending on local labor law or tax law rules or administrative conditions. This may mean, among other things, that continued vesting of employee stock options may take place in certain cases where this would not otherwise have been the case. The Board of Directors also has the right to bring forward the vesting and exercise date of employee stock options in certain cases, such as in the event of a public takeover bid, certain changes in the ownership of the company, liquidation, merger and similar measures.
11. Participation in the Employee Stock Option Program 2025/2029 presupposes that such participation can legally take place, and that such participation, in the Company's assessment, can take place with reasonable administrative costs and financial efforts.

B. Directed issue of warrants to the Company
In order to enable the Company's delivery of shares under the Program and to cover potential social security costs arising from the Program, the Board of Directors proposes that the Annual General Meeting resolves on a directed issue of not more than 5,500,000 warrants, of which not more than 5,000,000 warrants to ensure the Company's delivery of shares under the Program and not more than 500,000 warrants to cover any cash flow effects resulting from social security contributions due to the Program. The warrants issued for the purpose of covering such costs may either be sold directly or exercised for subscription of new shares, which may subsequently be sold to cover costs corresponding to the social security contributions. The issue is subject to the following terms.

1. The right to subscribe for the warrants shall, with deviation from the shareholders' preferential rights, belong to the Company. Oversubscription cannot occur.
2. The reason for the deviation from the shareholders’ pre-emption rights is that the issue forms a part in the introduction of Program 2025/2029 and to cover cash flow effects from potential social security costs arising from the Program.
3. The warrants are issued free of charge.
4. Subscription of the warrants shall be made by subscription on a subscription list within three weeks from the date of the resolution of the general meeting. The Board of Directors shall have the right to extend the subscription period.
5. The subscription price per share upon exercise of the warrant is SEK 0.1. However, the subscription price may not be less than the quota value of the Company's share. If the subscription price exceeds the quota value of the previous shares, the excess amount shall be recognized in the unrestricted share premium reserve.
6. Subscription of shares by virtue of the warrants shall be made in accordance with the terms and conditions of the warrants from 1st of November 2028 to 1st of May 2029.
7. The increase of the Company's share capital may, upon full exercise of the warrants, amount to a maximum of SEK 550,000 (taking into account the current quota value and provided that no recalculation is made in accordance with the terms of the warrants).
8. Shares issued as a result of new subscriptions carry the right to dividends for the first time on the record date for dividends that occurs immediately after the newly subscribed shares have been registered with the Swedish Companies Registration Office and the shares have been entered in the share register of Euroclear Sweden AB.
9. The Management Board, or the person appointed by it, is authorized to make the minor adjustments necessary for the registration and execution of the decision.

The complete terms and conditions for the warrants are set out in "Terms and conditions for warrants 2025/2029, Prostatype Genomics AB (publ)". The terms and conditions state, among other things, that the subscription price as well as the number of shares that each warrant entitles to subscribe for may be recalculated in certain situations.

C. Approval of transfer of warrants or shares in the Company
The board of directors proposes that the general meeting resolves to approve (i) that the Company may transfer a maximum number of warrants or shares in the Company corresponding to the allotment in item A3 above to participants in the Program, or otherwise dispose of the warrants to secure the Company's obligations under the Program in connection with the participants exercising the employee stock options to acquire shares, and (ii) that the Company may dispose of a maximum of 500,000 warrants to cover cash flow effects resulting from any social security contributions in accordance with the terms of the Program.

The Board of Directors is entitled to cancel the number of warrants that are not necessary in light of the allotment or for the warrants intended to cover any cash flow effects resulting from social security contributions in connection with the Program.

Miscellaneous
Costs for Program 2025/2029
The program has been designed in consultation with external legal and financial advisors and the costs for this advice are estimated to amount to a maximum of SEK 50 000 (excluding VAT).

In addition to the advisory costs, the Board of Directors estimates that the Program will incur costs in the form of social security contributions and administrative costs in connection with the subscription of shares with the support of the warrants and registration with the Swedish Companies Registration Office. These costs cannot be calculated with the required reliability at present, but since the proposal includes the issuance of warrants to cover cash flow effects as a result of any social security contributions, the Company's costs may be considered planned/managed in a satisfactory manner.

Previous incentive programs in the Company; dilution
No warrants have been allocated under the previously decided incentive programme 2022/2025.

The maximum dilution effect of the Program is estimated to amount to approximately ten (10) percent, provided that all options granted under the Program are exercised in full. The calculation has been made in relation to the number of registered outstanding shares and granted options in the Company as of October 31, 2025 (including options issued to cover any cash flow effects due to social security costs).

Item 17 – Resolution on general authorization to issue shares
The board of directors proposes that the general meeting resolves to authorize the board of directors for the period up to the next annual meeting of shareholders to resolve, on one or several occasions, to issue shares, warrants and/or convertible loans (or combinations thereof, so-called units). If the board of directors uses the authorization, it may also be done with a deviation from the shareholders' pre-emptive right and/or with provisions regarding in-kind or set-off.

An issue in accordance with this authorization shall be on market terms. The board of directors shall have the right to determine the terms and conditions regarding issues under this authorization and what persons shall be entitled to subscribe for issued securities. The reason why the board of directors should be able to resolve on an issue with a deviation from the shareholder's pre-emptive right and/or with a provision on in-kind or set-off is that the Company should have the opportunity to procure capital for the Company, carry out strategically motivated collaborations or business acquisitions and facilitate the implementation of issues in order to strengthen the Company's financial position.

The CEO, or whoever the board of directors appoints, shall have the right to make the minor adjustments that may be required in connection with registration of the resolution with the Swedish Companies Registration Office and Euroclear Sweden AB.
Majority requirements
The general meeting's approval of the board's rights issue resolution according to item 13 b) requires that the articles of association are amended in accordance with item 13 a). The resolution of the general meeting in accordance with item 13 a) and b) shall therefore be adopted as one resolution. Such a resolution is valid only if it has been supported by shareholders representing not less than two-thirds of both the votes cast and the shares represented at the general meeting. The same majority also applies to the resolutions according to item 14, 15 and 17 (the authorizations).

Resolutions according to A, B and C in item 16 above must be made as one decision and are thus conditional to each other. Resolutions according to this item requires, for its validity, a minimum of nine tenths of both the votes cast and the shares represented at the general meeting.

Handling of personal data
For information regarding the processing of your personal data, please refer to
https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf

Questions to the board of directors and the CEO
The board of directors and the CEO shall, if a shareholder requests it, and the board of directors considers that it can be done without significant damage to the Company, provide information about conditions that may affect the assessment of an item on the agenda or the Company’s financial situation. The request for such information shall be submitted in writing to the Company before the general meeting to the address Augustendalsvägen 20, 131 52 Nacka Strand, or via e-mail to info@prostatypegenomics.com.

Documentation
The annual report and audit report as well as other documents according to the Swedish Companies Act are kept available on the Company's website www.prostatypegenomics.com and at the Company's office at address Augustendalsvägen 20, 131 52 Nacka Strand. The documents are sent free of charge to shareholders who request it and who state their postal address.

Nacka Strand in April 2025
Prostatype Genomics AB (publ)
The board of directors

For more information about the Company, please contact:
Fredrik Rickman, CEO Prostatype Genomics AB
Telephone: +46 (0)73 049 77 01
E-mail: fredrik.rickman@prostatypegenomics.com

Certified Adviser
Carnegie Investment Bank AB (publ)
Telephone: +46 (0)73 856 42 65
E-mail: certifiedadviser@carnegie.se

About Prostatype Genomics
Prostatype® is a genomic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or no-treatment of prostate cancer. The test was developed by a leading research group at Karolinska Institute and is provided by Prostatype Genomics AB. The Company’s Certified Adviser is Carnegie Investment Bank AB.